Authors

Glenn J. Hanna, MD, Dana-Farber Cancer Institute

Latest:

Investigational Agents for the Treatment of Advanced cSCC

Dr Hanna highlights investigational agents that are being studied for the treatment of advanced cSCC and discuss some unmet needs for cSCC.

Shernan Holtan, MD

Latest:

Multidisciplinary Approaches to GVHD

Medical experts discuss multidisciplinary approaches to GVHD.

Suzanne B. Coopey, MD, FACS

Latest:

Dr Coopey on Institutional and Societal Initiatives to Support Women in Oncology

Suzanne B. Coopey, MD, FACS, discusses ways that women in oncology can feel further supported and advocated for in the cancer care space.

Ariana Pelosci

Latest:

T-DM1 Is Not Associated With Improved PFS vs Historical Controls in Pretreated HER2+ Biliary Tract Cancer

T-DM1 was found to be tolerable, but progression-free survival was not improved vs historical data in HER2-positive biliary tract cancer.

Neil Morganstein, MD

Latest:

The Future of Molecular Testing in NSCLC

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Naomi Dempsey, MD

Latest:

Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Ani Balmanoukian, MD, The Angeles Clinic and Research Institute

Latest:

Second-Line Treatment of SCLC

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

Ecaterina Ileana Dumbrava, MD

Latest:

Dr. Dumbrava on the Mechanism of Action of BDC-1001 in Advanced HER2-Expressing Breast Cancer

Ecaterina Ileana Dumbrava, MD, discusses the mechanism of action of BDC-1001 in advanced HER2-expressing breast cancer.

Christopher Cutie, M.D., Vice President, Disease Area Leader, Bladder Cancer, Janssen Research & Development, LLC.

Vice President Disease Area Leader, Bladder Cancer Janssen Research & Development, LLC.

Latest:

How Advancing the Science of Bladder Cancer Aims to Transform Patients’ Lives

Attaya Suvannasankha, MD

Latest:

Dr Suvannasankha on the Potential Mitigation of CRS With REGN5459 in R/R Myeloma

Attaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.

Joshua Hurwitz

Latest:

Hurwitz on the Safety Profile of Simultaneous Integrated Boost Plus SBRT in Prostate Cancer

Joshua Hurwitz discusses findings from a study investigating the safety of adding multifocal MRI-directed simultaneous integrated boost to stereotactic body radiation therapy in patients with prostate cancer.

Amit K. Verma, MBBS

Latest:

New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

Sidney Kimmel Cancer Center – Jefferson Health

Latest:

SKCC’s Dr. Edith Mitchell Named Enterprise Vice President for Cancer Disparities

Edith P. Mitchell, MD, MACP, FCCP, FRCP, Director of the Center to Eliminate Cancer Disparities and Clinical Professor of Medicine and Medical Oncology, has been named Enterprise Vice President for Cancer Disparities at Jefferson Health’s Sidney Kimmel Cancer Center.

Mario Spaggiari, MD

Latest:

Dr. Spaggiari on Surgical Strategies to Improve Liver Remnants in CRC With Liver Metastases

Mario Spaggiari, MD, discusses surgical strategies to improve liver remnants in colorectal cancer with liver metastases.

Jordyn Sava

Latest:

Frontline Nivolumab/Ipilimumab Prolongs OS in Unresectable HCC

Nivolumab plus ipilimumab produced a statistically significant and clinically meaningful OS benefit vs SOC in systemic therapy–naive unresectable HCC.

Roger Li, MD

Latest:

Dr Li on Safety Data Derived From the CORE-001 Trial in BCG-Unresponsive NMIBC

Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.

Jyoti Mayadev, MD

Latest:

Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical Cancer

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

Fernando C. Santini, MD

Latest:

Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Chandler Park, MD, MSc, FACP

Latest:

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

Drs Park and Leyfman discuss their commitment to advancing global medical education, mentoring future leaders, and bridging gaps in access to accurate health care information.

Boris A. Hadaschik, MD

Latest:

Dr. Hadaschik on Treatment After Apalutamide Progression in SPARTAN Trial

Boris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.